Ask the patient about cost effectiveness

Abstract

A sking patients to determine the value of drugs with questionable cost effectiveness could make the decision to withhold treatment ‘ more understandable and defensible ’, argues a new booklet from the UK’s Office of Health Economics. The report suggests performing ‘rough’ economic analyses to determine if a therapy is obviously cost effective or not, before deciding which treatments to present to patients, and considering the results when developing guidelines.